We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension (SDHDS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01062763
First Posted: February 4, 2010
Last Update Posted: May 8, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Ib Abildgaard Jacobsen, Odense University Hospital
  Purpose
The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.

Condition Intervention Phase
Arterial Hypertension Hypertension, Resistant to Conventional Therapy Diabetes Mellitus Drug: spironolactone Drug: placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: South Danish Hypertension and Diabetes Study

Resource links provided by NLM:


Further study details as provided by Ib Abildgaard Jacobsen, Odense University Hospital:

Primary Outcome Measures:
  • Change of of Systolic Blood Pressure [ Time Frame: 4 months ]
    Change of systolic blood pressure from baseline to study end at four months.

  • Change of Diastolic Blood Pressure [ Time Frame: 4 months ]
    Change of diastolic blood pressure from baseline to study end at four months.


Secondary Outcome Measures:
  • Adverse Effects [ Time Frame: 4 months ]

Enrollment: 119
Study Start Date: March 2010
Study Completion Date: May 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: addition of spironolactone
spironolactone is added to previous antihypertensive treatment
Drug: spironolactone
25 to 50 mg once daily
Placebo Comparator: Placebo
Addition of placebo
Drug: placebo
addition of placebo 1 to 2 tablets daily

Detailed Description:

The primary object of the study is to estimate the effect of addition of low dose spironolactone to antihypertensive treatment with at least three antihypertensive drugs in patients with type-2 diabetes and blood pressure over 130/80 mmHg.

Secondary aims are to estimate how many of these patients have their blood pressure controlled by the addition of spironolactone, to investigate whether the addition of spironolactone affects insulin sensitivity and urinary protein secretion and to estimate the incidence of adverse effects of the aldosterone antagonist.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age < 75 years
  • Type-2 diabetes
  • Therapy resistant hypertension (by ABPM)
  • Treatment with at least 3 antihypertensives

Exclusion Criteria:

  • HbA1c > 10.0
  • BP > 180/110 mmHg
  • Secondary hypertension
  • Intolerance to spironolactone
  • Permanent treatment with nonsteroidal antiinflammatory drugs or systemic glucocorticoids
  • Total cholesterol 10 mmol/l
  • New York Heart Association class III and IV
  • Pregnancy or planned pregnancy
  • Psychiatric disease
  • Malignant disease
  • Insufficient adherence
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01062763


Sponsors and Collaborators
Ib Abildgaard Jacobsen
Investigators
Principal Investigator: Ib A Jacobsen, DMSc Odense University Hospital
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Ib Abildgaard Jacobsen, Consultant physician, associate professor, Odense University Hospital
ClinicalTrials.gov Identifier: NCT01062763     History of Changes
Other Study ID Numbers: EudraCT 2009-017033-22
2009-017033-22 ( EudraCT Number )
First Submitted: February 3, 2010
First Posted: February 4, 2010
Results First Submitted: June 27, 2013
Results First Posted: May 8, 2014
Last Update Posted: May 8, 2014
Last Verified: April 2014

Keywords provided by Ib Abildgaard Jacobsen, Odense University Hospital:
hypertension
spironolactone
antihypertensive treatment
Type-2 diabetes

Additional relevant MeSH terms:
Hypertension
Diabetes Mellitus
Coronary Vasospasm
Vascular Diseases
Cardiovascular Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Coronary Disease
Myocardial Ischemia
Heart Diseases
Spironolactone
Mineralocorticoid Receptor Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Diuretics, Potassium Sparing
Diuretics
Natriuretic Agents